{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T11:06:19Z","timestamp":1777633579896,"version":"3.51.4"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Delivery of recombinant adeno-associated virus serotype 9 (rAAV9) into cerebrospinal fluid bypasses the blood\u2013brain barrier and can permit efficient brain tissue transduction. Whereas intracisterna magna injection (ICM) and other routes have been considered, lumbar intrathecal (IT) delivery offers a minimally invasive approach for treating genetic disorders of the central nervous system. To evaluate central nervous system biodistribution, we quantified vector genome (vg) copies of five rAAV9 vectors in cynomolgus macaques following ICM or lumbar IT delivery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 48 animals were followed across five studies: four lumbar IT infusion studies with four recombinant adeno-associated virus serotype 9 vectors (TSHA-101, -102, -105, and -120); and one ICM infusion study (TSHA-102 only). Stock vectors were diluted to dosing concentrations and 2.5\u202fmL were administered to each animal. After animals were sacrificed, tissue samples were harvested and biodistribution was assessed via qPCR.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Despite protocol differences specifying different doses (human effective dose range, 2.6\u202f\u00d7\u202f10\n                      <jats:sup>13<\/jats:sup>\n                      to 2.0\u202f\u00d7\u202f10\n                      <jats:sup>15<\/jats:sup>\n                      vg), necropsy times (1\u202fmonth to 1\u202fyear), and central nervous system tissues harvested, rAAV9 DNA levels in the brain and spinal cord were generally dose-dependent and consistent across tissues. At comparable doses and times, IT and ICM delivery led to widespread and consistent distribution of vector genomes, approximating 1 vg\/diploid host genome throughout the brain at the higher doses tested.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings support IT administration as an effective, minimally invasive approach to central nervous system-directed gene therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1819594","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T04:44:42Z","timestamp":1777437882000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["rAAV9 vector biodistribution in nonhuman primate brain and spinal cord following lumbar intrathecal infusion"],"prefix":"10.3389","volume":"13","author":[{"given":"Emdadul","family":"Haque","sequence":"first","affiliation":[{"name":"Taysha Gene Therapies","place":["Dallas, TX, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nino","family":"Devidze","sequence":"additional","affiliation":[{"name":"Taysha Gene Therapies","place":["Dallas, TX, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suku","family":"Nagendran","sequence":"additional","affiliation":[{"name":"Taysha Gene Therapies","place":["Dallas, TX, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rumana","family":"Haque-Ahmed","sequence":"additional","affiliation":[{"name":"Taysha Gene Therapies","place":["Dallas, TX, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean","family":"McAuliffe","sequence":"additional","affiliation":[{"name":"Taysha Gene Therapies","place":["Dallas, TX, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Lamontagne","sequence":"additional","affiliation":[{"name":"Taysha Gene Therapies","place":["Dallas, TX, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Ashkenas","sequence":"additional","affiliation":[{"name":"Taysha Gene Therapies","place":["Dallas, TX, United States"]},{"name":"EquiPoise Communication","place":["Toronto, ON, Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven J.","family":"Gray","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Texas Southeastern Medical Center","place":["Dallas, TX, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fred","family":"Porter","sequence":"additional","affiliation":[{"name":"Taysha Gene Therapies","place":["Dallas, TX, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.pediatrneurol.2016.10.022","article-title":"Intracerebroventricular delivery as a safe, long-term route of drug administration","volume":"67","author":"Cohen-Pfeffer","year":"2017","journal-title":"Pediatr Neurol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"115363","DOI":"10.1016\/j.addr.2024.115363","article-title":"Adeno-associated virus vector delivery to the brain: technology advancements and clinical applications","volume":"211","author":"Ye","year":"2024","journal-title":"Adv Drug Deliv Rev"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"101602","DOI":"10.1016\/j.omtm.2025.101602","article-title":"Impact of pre-existing immunity on safety and biodistribution of a single AAV9 vectorintrathecal injection in cynomolgus monkeys","volume":"33","author":"Vono","year":"2025","journal-title":"Mol Ther Methods Clin Dev"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/gt.2012.101","article-title":"Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates","volume":"20","author":"Gray","year":"2013","journal-title":"Gene Ther"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1089\/hum.2017.026","article-title":"Evaluation of intrathecal routes of administration for adeno-associated viral vectors in large animals","volume":"29","author":"Hinderer","year":"2018","journal-title":"Hum Gene Ther"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1089\/hum.2022.163","article-title":"Biodistribution of adeno-associated virus gene therapy following cerebrospinal fluid-directed administration","volume":"34","author":"Chen","year":"2023","journal-title":"Hum Gene Ther"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3390\/genes15010031","article-title":"The efficacy of a human-ready mini MECP2 gene therapy in a pre-clinical model of Rett syndrome","volume":"15","author":"Sadhu","year":"2023","journal-title":"Genes"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/mt.2015.187","article-title":"Production of recombinant adeno-associated virus vectors using suspension HEK293 cells and continuous harvest of vector from the culture media for GMP FIX and FLT1 clinical vector","volume":"24","author":"Grieger","year":"2016","journal-title":"Mol Ther"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1177\/1091581817741840","article-title":"Toxicology evaluation of drugs administered via uncommon routes: intranasal, intraocular, intrathecal\/intraspinal, and intra-articular","volume":"37","author":"Emami","year":"2018","journal-title":"Int J Toxicol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/gt.2012.6","article-title":"Intracellular transport of recombinant adeno-associated virus vectors","volume":"19","author":"Nonnenmacher","year":"2012","journal-title":"Gene Ther"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1011143","DOI":"10.3389\/fimmu.2022.1011143","article-title":"Organoids and microphysiological systems: promising models for accelerating AAV gene therapy studies","volume":"13","author":"Ramamurthy","year":"2022","journal-title":"Front Immunol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1038\/mt.2011.72","article-title":"Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates","volume":"19","author":"Gray","year":"2011","journal-title":"Mol Ther"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1038\/mt.2008.171","article-title":"Self-complementary AAV vectors; advances and applications","volume":"16","author":"McCarty","year":"2008","journal-title":"Mol Ther"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"14051","DOI":"10.1038\/mtm.2014.51","article-title":"Widespread gene transfer in the central nervous system of cynomolgus macaques following delivery of AAV9 into the cisterna magna","volume":"1","author":"Hinderer","year":"2014","journal-title":"Mol Ther Methods Clin Dev"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.omtm.2018.06.003","article-title":"Toxicology study of intra-cisterna magna adeno-associated virus 9 expressing human alpha-L-iduronidase in rhesus macaques","volume":"10","author":"Hordeaux","year":"2018","journal-title":"Mol Ther Methods Clin Dev"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.omtm.2018.12.001","article-title":"Kinetics and MR-based monitoring of AAV9 vector delivery into cerebrospinal fluid of nonhuman primates","volume":"13","author":"Ohno","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"e0122453","DOI":"10.1371\/journal.pone.0122453","article-title":"Pharmacokinetics and bioavailability of a therapeutic enzyme (idursulfase) in cynomolgus monkeys after intrathecal and intravenous administration","volume":"10","author":"Xie","year":"2015","journal-title":"PLoS One"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"e0164765","DOI":"10.1371\/journal.pone.0164765","article-title":"Biodistribution of idursulfase formulated for intrathecal use (idursulfase-IT) in cynomolgus monkeys after intrathecal lumbar administration","volume":"11","author":"Chung","year":"2016","journal-title":"PLoS One"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"e30341","DOI":"10.1371\/journal.pone.0030341","article-title":"CNS penetration of intrathecal-lumbar idursulfase in the monkey, dog and mouse: implications for neurological outcomes of lysosomal storage disorder","volume":"7","author":"Calias","year":"2012","journal-title":"PLoS One"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12987-024-00556-2","article-title":"Evaluating the effect of injection protocols on intrathecal solute dispersion in non-human primates: an in vitro study using a cynomolgus cerebrospinal fluid system","volume":"21","author":"Burla","year":"2024","journal-title":"Fluids Barriers CNS"},{"key":"ref21","author":"Haque","year":"2023"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1093\/brain\/awab182","article-title":"Engineered microRNA-based regulatory element permits safe high-dose miniMECP2 gene therapy in Rett mice","volume":"144","author":"Sinnett","year":"2021","journal-title":"Brain"},{"key":"ref23","author":"Rossignol","year":"2025"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.omtm.2018.10.011","article-title":"Efficacy of a bicistronic vector for correction of Sandhoff disease in a mouse model","volume":"12","author":"Woodley","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.omtm.2018.02.005","article-title":"Development of intrathecal AAV9 gene therapy for giant axonal neuropathy","volume":"9","author":"Bailey","year":"2018","journal-title":"Mol Ther Methods Clin Dev"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1056\/NEJMoa2307952","article-title":"Intrathecal gene therapy for giant axonal neuropathy","volume":"390","author":"Bharucha-Goebel","year":"2024","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1819594\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T04:44:50Z","timestamp":1777437890000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1819594\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":26,"alternative-id":["10.3389\/fmed.2026.1819594"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1819594","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]},"article-number":"1819594"}}